Selective androgen receptor modulators (SARMs) have been identified as a promising class of drug candidates potentially applicable to diverse pathological conditions commonly associated with significantly reduced muscle mass. Due to a suspected and meanwhile repeatedly proven misuse of SARMs in elite and amateur sport, sustaining constantly updated doping control analytical methods is critical for sports drug testing laboratories. These test methods predominantly utilize mass spectrometry-based instrumentations and, consequently, studies on the mass spectrometric behavior of new compounds and, where available, their metabolic products are vital for comprehensive doping controls. In this communication, the dissociation patterns of three new SARM drug candidates referred to as GSK2881078, PF-06260414, and TFM-4 AS-1 as observed under electron ionization as well as electrospray ionization/collision-induced dissociation are discussed. By means of high resolution/high accuracy tandem mass spectrometry employing quadrupole-orbitrap mass analyzers, information on precursor-product ion relationships and elemental compositions was obtained and subsequently utilized to suggest dissociation routes of the target compounds. This information can contribute to future studies concerning structure assignments of metabolites and accelerate the identification of related substances if distributed and/or illicitly used in the world of sport.
Introduction
High resolution/high accuracy mass spectrometry (HRMS) has allowed for in-depth investigations into the mass spectrometric and (collision-induced) dissociation behavior of drugs and drug candidates, revealing characteristic features and patterns typical for specific pharmacophores and functional groups. 1 This information is routinely utilized to detect and identify target analytes and related compounds in complex biological matrices in various fields of analytical chemistry, 2 including sports drug testing. 3 Here, the misuse of (yet) non-approved therapeutics and 'tailored' derivatives has been a growing issue and, hence, complementing and updating the laboratories' databases with new mass spectral data is critical for comprehensive doping controls. [4] [5] [6] A class of compounds particularly relevant for sports drug testing is referred to as selective androgen receptor modulators (SARMs), which has been prohibited by the World Anti-Doping Agency (WADA) since 2008. 7 Albeit no SARM has yet received full clinical approval, 8, 9 a substantial number of drug candidates was or is currently in development for the prevention or treatment of conditions largely associated with significant losses of muscle mass (Table 1) , including cachexia, sarcopenia, but also other pathologies. [10] [11] [12] The drug candidates' proven ability to stimulate muscle growth as demonstrated in (pre)clinical trials has been incentive for Internet-based vendors selling to and profiting from interested athletes from both the amateur and professional level, which has resulted in a continuously increasing number of adverse analytical findings in doping controls since 2010. 13 Sports drug testing laboratories are thus advised to proactively expand their analytical portfolio to cover the steadily growing list of substances reportedly exhibiting SARM-like properties. This necessitates detailed knowledge about the analytes' analytical behavior, which varies considerably with the substances' enormous structural heterogeneity and, hence, individual studies on these compounds' mass spectrometry are warranted.
14 In this communication, the SARM drug candidates referred to as GSK2881078, PF-06260141, and TFM-4 AS-1 were subjected to electrospray ionization (ESI)-high resolution/ HRMS and electron ionization (EI)-HRMS to investigate the analytical 'fingerprint' of these substances, supporting future test method developments and drug metabolism studies. The use of state-of-theart quadrupole/orbitrap-based mass analyzers allowed for corroborating the proposed dissociation and fragmentation pathways by providing elemental compositions of the observed (product) ions in MS and tandem mass spectrometry (MS/MS) measurements. With experimental mass errors below 3 ppm in both gas chromatography (GC)-and liquid chromatography-high resolution mass spectrometry (LC-HRMS), the presence (or absence) of heteroatoms was indicative for the moiety of the ions' origin.
Experimental
ESI-MS(/MS) analyses were conducted using a Q Exactive plus mass spectrometer (Thermo Fisher, Dreieich, Germany), operated at a resolution of 60,000 (at m/z 200, full width at half maximum) in full scan and targeted horizontal component distance (HCD) mode. Positive and negative ionization was done at 3.5 kV and À3 kV, respectively, and collision energies in MS/MS experiments were adjusted to allow for efficient dissociation of precursor ions that were isolated with a window of 1 m/z. The collision gas was nitrogen, delivered from a N 2 generator (CMC, Eschborn, Germany). For (pseudo)MS 3 experiments, in-source CID was utilized to generate respective precursor ions for subsequent targeted HCD. Target analytes were dissolved at 1 mg/mL in acetonitrile/water (1:1, v/v) and introduced into the ESI source by a syringe pump at a flow rate of 5 mL/min.
For GC-EI-MS(/MS) analyses, the analytes were dissolved at 50 mg/mL in a mixture of N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA), ammonium iodide, and ethanethiol (100: 0.2: 0.6, v/w/v) and incubated at 60 C for 20 min prior to injection into Q Exactive GC Orbitrap (Thermo Fisher). The GC (Trace 1310) was equipped with a HP Ultra1 capillary column (Agilent, Waldbronn, Germany), film thickness 0.11 mm, i.d. 0.2 mm, and length 17 m. The carrier gas helium was used with a constant pressure of 16.2 lbf/in 2 (11.2 bar) and the injection volume was 2 mL (split ratio, 1:6). A temperature gradient starting at 183 C, increasing at 3 C/min to 233 C and then at 40 C to 310 C (maintained at 310 C for 2 min) was used. The transfer line temperature consisted of three zones set to 300 C, 280 C, and 260 C (from GC to MS), the ion source temperature was 250 C, and the mass range (full scan and MS/MS experiments) was m/z 50-700. The ionization mode was positive EI at 50 eV and the instrument was operated at a resolution of 60,000 (at m/z 200, full width at half maximum). Both instruments were operated via Xcalibur (Thermo Fisher, versions 3.0.63 and 4.0.27.19, respectively).
Reference materials of GSK2881078, PF-0626014, and TFM-4 AS-1 were obtained from Biomol GmbH (Hamburg, Germany) and Sigma (Schnelldorf, Germany), respectively.
Results and discussion
SARMs include a considerable variety of chemical core structures, which can principally be classified into steroidal and non-steroidal compounds. The drug entities have shown to exhibit substantially different physicochemical properties, and information on the substances' ionization and dissociation under commonly utilized analytical conditions employed in doping control laboratories is critical to routine sports drug testing programs. In continuation of recent studies and reviews, 13 mass spectral data of three additional SARMs comprising of indole-, isoquinoline-, and steroid-related pharmacophores from GSK2881078 ( 
GSK2881078
Following promising preclinical studies, the SARM drug candidate GSK2881078 ( Figure 1 , 1) recently underwent phase-I clinical trials concerning safety, pharmacokinetics, and pharmacological effects, 15 and in the light of the disclosed structure and principle availability of the substance, a timely implementation into routine doping controls is indicated.
ESI-MS(/MS)
The protonated molecule of GSK2881078 is found at m/z 331 that is suggested to eliminate hydrogen fluoride (HF) (20 u), methanesulfinic acid (80 u), and the combination of both to form the product ions at m/z 311, 251, and 231, respectively (Figure 2(a) ). In addition, the heterolytic and homolytic cleavages causing the loss of 1-(methylsulfonyl)propene (120 u) and the radical of 1-(methylsulfonyl)propane (121 u), respectively, are proposed to form the protonated 4-(trifluoromethyl)-1H-indole-5-carbonitrile and the corresponding radical cation at m/z 211 and 210 ( Table 2 , Scheme 1). The product ion at m/z 211 was further found to generate the ion at m/z 191 upon further collisional activation by eliminating HF (20 u). Complementary, involving charge retention at the alkyl side chain, the product ion at m/z 121 is suggested to consist the cation of 1-(methylsulfonyl)propane as illustrated and summarized in Scheme 1. These product ions comprehensively cover the main features of the SARM drug candidate, which supports assigning modifications to the molecule, e.g. in future drug metabolism studies.
GC-EI-MS(/MS)
The EI full scan mass spectrum of GSK2881078 is illustrated in Figure 3 (a) that, noteworthy, bears a considerable resemblance to the ESI-MS/MS spectrum depicted in Figure 2 (a). Besides the molecular ion at m/z 330, the elimination of a fluorine radical (19 u) to form the fragment ion at m/z 311 is observed; however, in MS/MS experiments using m/z 330 as precursor ion, no product ion at m/z 311 is obtained (Table 3) , indicating an immediate ionization-induced loss of the fluorine radical. Conversely, the neutral loss of methanesulfinic acid (80 u) forming the fragment ion at m/z 250, as well as the elimination of the radical of (methylsulfonyl)methane yielding the ion at m/z 237 as attributed to a classical a-cleavage, are obtained from m/z 330 in MS/MS experiments (Scheme 2). Further, the fragment ion at m/z 217 was shown to result from m/ z 237 due to the loss of HF (20 u 
PF-06260414
In contrast to the aforementioned SARM (1), the development of PF-06260414 (6-[(4R)-tetrahydro-4-methyl-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl]-1-isochinoline carbonitrile, Figure 1 , 2) was recently discontinued after phase-I clinical trials concerning safety, pharmacokinetics, and pharmacodynamics were studied and evaluated also ethnic differences. 16 However, the lack of further clinical studies or even clinical approval does not exclude the drug candidate's misuse in sport as proven manifold in the past.
ESI-MS(/MS)
The isoquinoline-derived PF-06260414 generates an abundant protonated molecule at m/z 303 that dissociates upon collisional activation into a series of distinct and diagnostic product ions as depicted in Figure 2(b) . The majority of these product ions is suggested to result from sequential cleavages within the thiadiazinane 1,1-dioxide moiety as corroborated by high resolution/ accurate mass measurements and (pseudo)MS 3 experiments (Scheme 3). A neutral loss of 64 u, characteristic for the presence of a sulfonyl residue, 17 is observed, forming the product ion at m/z 239 from m/z 303. Further dissociation processes of m/z 239 lead to the product ion at m/z 210, which was tentatively assigned to the protonated molecule of 6-(propylideneamino)isoquinoline-1-carbonitrile as generated by the elimination of methanimine (29 u). Alternatively, m/z 210 can potentially be formed also immediately from the protonated molecule of the intact PF-06260414. The product ion at m/z 232 is proposed to represent the protonated 6-(sulfonylamino)isoquinoline-1-carbonitrile, generated by a neutral loss of C 4 H 9 N (71 u, e.g. methylpropenamine, methylazetidine) from m/z 303. Here, the subsequent loss of sulfur dioxide (64 u) was shown to form the product ion at m/z 168 (Table 2) , tentatively assigned to the dehydrogenated cation of 6-aminoisoquinoline-1-carbonitrile (e.g. 6-imino-5,6-dihydroisoquinoline-1-carbonitrile, Scheme 3). A particularly interesting dissociation route was observed for the generation of m/z 197 and product ions derived thereof. In (pseudo)MS 3 studies, m/z 239 was identified as the precursor of m/z 197, which eliminates propene to form a product ion with a tentatively assigned 6-positioned methylenehydrazine moiety at the isoquinoline nucleus (Scheme 3). The subsequent loss of HCN (27 u) gave rise to the product ion at m/z 170, consequently considered as protonated 6-aminoisoquinoline-1-carbonitrile, which was corroborated and substantiated by MS/MS data of m/z 170 that exhibited the presence of m/z 153 as the result of the loss of ammonia (17 u). Of note was however the identification of a product ion at m/z 161 in the MS/MS spectrum of m/z 170, which was composed of C 9 H 9 ON 2 . Since the precursor ion at m/z 170 did not contain any oxygen (Table 2) , an intermediately formed hydrated ion at m/z 188 is postulated, which subsequently eliminates HCN (27 u) to yield the ion at m/z 161. Similar phenomena were reported earlier especially for quinoline-based analytes, 18 and the herein studied compound can be considered as an additional substance exhibiting analogous behaviors.
GC-EI-MS(/MS)
Under the chosen sample preparation conditions, PF-06260414 was trimethylsilylated before injected into the GC-MS system, and the resulting EI full scan mass spectrum is shown in Figure 3(b) . In comparison to the corresponding ESI-MS/MS spectrum of the underivatized analyte, some similarities as well as unique features were identified. The molecular ion at m/z 374 readily eliminates a methyl radical (15 u) to form the fragment ion at m/z 359, which subsequently yielded the fragment ion at m/z 266. The underlying mechanism of the formation and potential structure of m/z 266 are largely unclear, and merely a suggestion based on the elemental composition of C 15 H 16 N 3 Si (Table 3) was attempted. In consideration of the accurate mass of the ion and the facts that one silicon and three nitrogen atoms are retained in the fragment ion, the generation of a tricyclic pyridoquinoline-derived core is conceivable that would accommodate all proven aspects (Scheme 4). Further, m/z 359 eliminated SO 2 to form the low abundant ion at m/z 295, which subsequently dissociated into m/z 253 by the loss of propene (42 u). Also the generation of the radical cation at m/z 332 was attributed to the loss of propene (42 u) but from the molecular ion (m/z 374), and m/z 332 subsequently yielded the base peak fragment ion at m/z 181 (as shown in MS/MS experiments), which corresponds to m/z 182 observed in the ESI-MS/MS spectrum of the analyte (Figure 2(b) , Scheme 3).
TFM-4 AS-1
To the authors' knowledge, only preclinical data are available for TFM-4 AS-1 (Figure 1, 3) , which demonstrated its anabolic effects in animals. 19 
ESI-MS(/MS)
The steroidal SARM drug candidate TFM-4 AS-1 was studied using ESI in negative and positive ionization modes, and complementary information was obtained as depicted in Figure 2(c) and (d) , respectively. Deprotonation of the analyte results in the ion at m/z 473, which gave rise to one abundant product ion at m/z 160, which was assigned to deprotonated 2-(trifluoromethyl)aniline as illustrated in Scheme 5(a). Additional product ions were found at m/z 459 and 322, which were attributed to the losses of methane (16 u) and the steroidal A/B-ring structure (151 u), methyl group rearrangement from the 4-positioned nitrogen towards the leaving group was considered, resulting in the tentatively suggested structure shown in Scheme 5(b). More information provided, e.g. by stable isotope labeling of the methyl group would be desirable to elucidate the underlying mechanism; however, synthesis of these structures was not accomplished yet. The fact that the ion at m/z 407 produced the product ion at m/z 196 supports the aforementioned structure as this represents (by elemental composition) the cation of N-(6-(difluoromethylene)cyclohexadienylidene)propionamide, which necessitates the intact 
GC-EI-MS(/MS)
Using GC-MS, both the underivatized and the trimethylsilylated TFM-4 AS-1 were obtained under the chosen analytical conditions, and respective full scan mass spectra are depicted in Figure 3 (c) and (d). The underivatized analyte's molecular ion is observed at m/z 474, and a variety of diagnostic fragment ions is detected offering information similar to the MS/MS spectrum obtained after positive ESI (Figure 2(d) ). Via the central fragment ion at m/z 314, which is proposed to result from the elimination of a 2-(trifluoromethyl)aniline radical (160 u), the fragment ion at m/z 286 is obtained, which was assigned to the steroidal core structure in accordance to earlier results (vide supra). Through an alternative dissociation route, m/z 314 also yields the fragment ion at m/z 298 (Table 3) , attributed to the loss of methane from C-13 as subsequent MS/MS experiments allowed for the formation of m/z 136 that is suggested to include the A-ring-attached methyl groups (Scheme 6), hence corroborating the proposed origin of the leaving group. In agreement with Figure 2 Trimethylsilylation of TFM-4 AS-1 resulted in noteworthy alterations of the fragmentation pattern of the analyte. While the ions at m/z 546, 531, and 386 are attributable to corresponding counterparts of the underivatized TFM-4 AS-1 (at m/z 374, 359, and 314, respectively) considering an increment of 72 u caused by the introduction of a trimethylsilyl (TMS) residue, the formation of m/z 386 in particular necessitates the presence of the TMS moiety at a location other than amide nitrogen. In order to account for the elemental composition determined for m/z 386 (C 23 H 36 O 2 NSi), trimethylsilylation of the analyte at the amide oxygen is required either through derivatization of the imidic acid tautomer of the analyte or by a rearrangement of the TMS group during dissociation. MS/MS data obtained from m/z 386 furnished additional evidence by demonstrating the loss of trimethylsilanol (90 u), which is typically observed in case of -O-TMS-containing analytes, which in this case led to the formation of the low abundant fragment ion at m/z 296 (Scheme 7). Base peak of the EI-MS spectrum of trimethylsilylated TFM-4 AS-1 was the ion at m/z 288 that is suggested to represent the intact D-ring substituent including the steroidal carbons C-16 and C-17, which (upon collisional activation) produced the fragment ion at m/z 196.0569 for which the same structure is proposed as for the underivatized analyte (Scheme 6). Of note, another species at m/z 196.1153 was observed in the EI full scan spectrum, which was found to originate from the ion at m/z 331 (Table 3 ) and, thus, is proposed to consist of components of the steroidal C/D-ring plus the dimethylsilylated amide functionality. 
